Cardiovascular Division, King's College London, Rayne Institute, St Thomas' Hospital London, SE17EH, United Kingdom.
US FDA, Office of Clinical Pharmacology and Office of Translational Science Sci Silver Spring, MD 20903, USA.
Pharmacol Res Perspect. 2015 Aug;3(4):e00164. doi: 10.1002/prp2.164. Epub 2015 Jul 24.
The pharmacology research sector is changing to accommodate a need for greater transparency and better standards. The themed articles contained herein explain how Pharmacology Research and Perspectives (PR&P) has responded to this agenda. This issue of PR&P contains three articles that consider the reliability of pharmacological research publications, and approaches to their improvement in this regard. This first article explains the importance of publishing findings that confirm or repudiate published findings (so called "replication" studies). It also emphasizes that PR&P actively encourages submission of such articles, and seeks to oppose the publication bias that favors publication of "positive" findings. The second paper explores some initiatives to publish "negative" clinical findings, including a PR&P initiative. The final paper elaborates a toolkit that can be applied to drug discovery research to facilitate the reliability of findings.
药理学研究领域正在发生变化,以适应更高透明度和更好标准的需求。本文包含的专题文章解释了药理学研究与展望 (PR&P) 如何应对这一议程。本期 PR&P 包含三篇文章,探讨了药理学研究出版物的可靠性,以及改进这方面的方法。本文首先解释了发表证实或反驳已发表研究结果的发现的重要性(所谓的“重复”研究)。它还强调 PR&P 积极鼓励提交此类文章,并试图反对有利于发表“阳性”发现的发表偏倚。第二篇论文探讨了一些发表“阴性”临床发现的举措,包括 PR&P 的举措。最后一篇论文详细阐述了一个可应用于药物发现研究的工具包,以促进研究结果的可靠性。